Claritas Pharmaceuticals(OTC) CLAZF

Market CapN/A

Since IPO (2017)-100%

5 Year-100%

1 Year+0%

1 Month+0%

$0.00

+0.00%

+0.00Today

Claritas Pharmaceuticals last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-05-07

Claritas Pharmaceuticals stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-02-27
1 month	+0%	USD 0.00	2026-02-27
3 month	+0%	USD 0.00	2025-12-16
Year to date	+0%	USD 0.00	2025-12-16
1 year	+0%	USD 0.00	2025-04-23
3 year	+0%	USD 0.00	2023-05-01
5 year	-100%	USD 0.58	2021-05-07
Since inception	-100%	USD 14.46	2017-01-11

Claritas Pharmaceuticals Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$4.72M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1063.99 (High)

Dividend

$0.00

Beta (Volatility)

1063.99 (High)

Price

$0.00

Volume

15,000

Open

$0.00

Price

$0.00

Volume

15,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 31, 2026

Dividend

$0.00

Beta (Volatility)

1063.99 (High)

Price

$0.00

Volume

15,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 31, 2026

CLAZF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Claritas Pharmaceuticals

Claritas Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing medical therapies to address significant unmet patient needs. Established in 2014 and rebranded in 2021, the company is headquartered in San Rafael, California.

Products and Services

Development of innovative medical therapies
Focus on addressing unmet patient needs
Specialty pharmaceuticals in clinical stages

Growth Outlook

Potential for significant market impact with unique therapies
Established in 2014, with ongoing development initiatives
Rebranding in 2021 aims to enhance market presence

Financial Highlights

Recent quarterly net income of $181,000 in Q3 2021
Trailing twelve months (TTM) revenue of $0
Current ratio of 0.14 indicates liquidity challenges

Claritas Pharmaceuticals, Inc. operates in the biotechnology sector, focusing on the development of specialized medical therapies. The company has made strides in its growth trajectory since its inception, with a rebranding effort aimed at enhancing its market presence. Despite facing challenges, including a current ratio of 0.14, the company reported a net income of $181,000 in the most recent quarter, indicating potential for future profitability. The absence of revenue in the trailing twelve months highlights the early-stage nature of its operations, emphasizing the importance of ongoing development initiatives. Investors may find interest in the company's commitment to addressing significant patient needs through innovative therapies.

AI Generated • Aug 19, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

San Rafael, CA 94903, US

CLAZF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-436.27%

Return on Capital

-134.70%

Return on Assets

40.31%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

15.00K

Avg. Volume

Financials (TTM)

Gross Profit

$0.00

Operating Income

$770.00K

EBITDA

-$2.64M

Operating Cash Flow

-$953.00K

Capital Expenditure

$0.00

Free Cash Flow

-$953.00K

Cash & ST Invst.

$2.00K

Total Debt

$548.00K

Claritas Pharmaceuticals Performance Analysis

Claritas Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2020-12-31	N/A
Q1	2021-03-31	N/A
Q2	2021-06-30	N/A
Q3	2021-09-30	N/A

Claritas Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2020-12-31	-58.6%
Q1	2021-03-31	-246.9%
Q2	2021-06-30	30.4%
Q3	2021-09-30	108.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q3 2021YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

$181.00K

+143.8%

EBITDA

$695.00K

-32.7%

Quarterly Fundamentals

Name

Q3 2021YOY CHG

Total Cash

$2.00K

-99.6%

Total Debt

$548.00K

-38.8%

Accounts Receivable

$102.00K

-38.2%

Inventory

$16.03K

+9814.5%

Long Term Debt

$10.00K

-85.5%

Short Term Debt

$538.00K

-34.9%

Return on Assets

40.31%

N/A

Return on Invested Capital

-98.76%

N/A

Free Cash Flow

-$281.00K

-205.2%

Operating Cash Flow

-$281.00K

-205.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TBGNFOxurion N.V.

TBGNFOxurion N.V.$0.17+0.00%

CCHWFColumbia Care Inc.

CCHWFColumbia Care Inc.$0.94-21.71%

SSIISS Innovations International, Inc.

SSIISS Innovations International, Inc.$3.59-0.69%

TRSSFTerrAscend Corp.

TRSSFTerrAscend Corp.$1.72-11.79%

IMUNImmune Therapeutics, Inc.

IMUNImmune Therapeutics, Inc.$0.09-7.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$120.60-0.01%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$47.03+0.02%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$43.68+0.06%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$71.17+0.01%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$39.02-0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.77+0.10%

CONLGraniteShares ETF Trust - GraniteShares 2x Long Coin Daily ETF

CONLGraniteShares ETF Trust - GraniteShares 2x Long Coin Daily ETF$6.25+0.16%

Questions About CLAZF

What is the current price of Claritas Pharmaceuticals?

Claritas Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Claritas Pharmaceuticals?

Over the past 52 weeks, Claritas Pharmaceuticals has traded between $0.00 and $0.00.

How much debt does Claritas Pharmaceuticals have?

Claritas Pharmaceuticals total debt is unavailable.

How much cash does Claritas Pharmaceuticals have on hand?

Claritas Pharmaceuticals does not have cash on hand data available.

What is Claritas Pharmaceuticals’s dividend yield?

Claritas Pharmaceuticals does not currently have a dividend yield.

Claritas Pharmaceuticals(OTC) CLAZF

Claritas Pharmaceuticals Financials at a Glance

CLAZF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Claritas Pharmaceuticals

CLAZF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Claritas Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CLAZF

What is the current price of Claritas Pharmaceuticals?

What is the 52-week range for Claritas Pharmaceuticals?

How much debt does Claritas Pharmaceuticals have?

How much cash does Claritas Pharmaceuticals have on hand?

What is Claritas Pharmaceuticals’s dividend yield?

Premium Investing Services